Camzyos(mavacamten)
Camzyos (mavacamten) is a small molecule pharmaceutical. Mavacamten was first approved as Camzyos on 2022-04-28. It has been approved in Europe to treat hypertrophic cardiomyopathy.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| cardiovascular diseases | D002318 |
Trade Name
FDA
EMA
Camzyos
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Mavacamten
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| CAMZYOS | Bristol Myers Squibb | N-214998 RX | 2022-04-28 | 4 products, RLD |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| camzyos | New Drug Application | 2025-04-17 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
MAVACAMTEN, CAMZYOS, BRISTOL | |||
| 2029-04-28 | ODE-398 | ||
| 2027-04-28 | NCE | ||
| 2026-06-15 | M-297 | ||
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
39 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hypertrophic cardiomyopathy | D002312 | EFO_0000538 | I42.1 | 2 | 4 | 7 | 3 | 15 | 30 |
| Cardiomyopathies | D009202 | EFO_0000318 | I42 | 2 | 4 | 7 | 1 | 12 | 25 |
| Hypertrophy | D006984 | EFO_0002460 | — | 1 | 4 | 7 | 1 | 9 | 21 |
Indications Phases 3
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Ventricular outflow obstruction | D014694 | EFO_1001448 | — | — | 1 | — | — | 1 | 2 |
| Left ventricular outflow obstruction | D000092242 | — | — | — | 1 | — | — | 1 | 2 |
| Heart failure | D006333 | EFO_0003144 | I50 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 7 | — | — | — | — | 7 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pregnancy rate | D018873 | — | — | — | — | — | — | 1 | 1 |
| Breast feeding | D001942 | — | — | — | — | — | — | 1 | 1 |
| Radiofrequency ablation | D000078703 | — | — | — | — | — | — | 1 | 1 |
| Ischemia | D007511 | EFO_0000556 | — | — | — | — | — | 1 | 1 |
| Myocardial ischemia | D017202 | EFO_1001375 | I20-I25 | — | — | — | — | 1 | 1 |
| Echocardiography | D004452 | — | — | — | — | — | — | 1 | 1 |
| Cardiac imaging techniques | D057791 | — | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Mavacamten |
| INN | mavacamten |
| Description | Mavacamten, sold under the brand name Camzyos, is a medication used to treat obstructive hypertrophic cardiomyopathy.
|
| Classification | Small molecule |
| Drug class | allosteric cardiac myosin modulators |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CC(C)n1c(=O)cc(N[C@@H](C)c2ccccc2)[nH]c1=O |
Identifiers
| PDB | — |
| CAS-ID | 1642288-47-8 |
| RxCUI | — |
| ChEMBL ID | CHEMBL4297517 |
| ChEBI ID | — |
| PubChem CID | 117761397 |
| DrugBank | DB14921 |
| UNII ID | QX45B99R3J (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Camzyos – Bristol Myers Squibb
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,059 documents
View more details
Safety
Black-box Warning
Black-box warning for: Camzyos
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
3,244 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use